235 related articles for article (PubMed ID: 23216455)
1. Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment.
Reményi G; Szász R; Debreceni IB; Szarvas M; Batár P; Nagy B; Kappelmayer J; Udvardy M
Platelets; 2013; 24(6):486-92. PubMed ID: 23216455
[TBL] [Abstract][Full Text] [Related]
2. Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia.
Tsantes AE; Nikolopoulos GK; Tsirigotis P; Zoi K; Zomas A; Kapsimali V; Kopterides P; Chondropoulos S; Dervenoulas J; Mantzios G
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):457-62. PubMed ID: 21836466
[TBL] [Abstract][Full Text] [Related]
3. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
4. Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.
Panova-Noeva M; Marchetti M; Spronk HM; Russo L; Diani E; Finazzi G; Salmoiraghi S; Rambaldi A; Barbui T; Ten Cate H; Falanga A
Am J Hematol; 2011 Apr; 86(4):337-42. PubMed ID: 21442635
[TBL] [Abstract][Full Text] [Related]
5. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
[TBL] [Abstract][Full Text] [Related]
6. The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.
Treliński J; Tybura M; Smolewski P; Robak T; Chojnowski K
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):646-51. PubMed ID: 19741509
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.
Cella G; Marchetti M; Vianello F; Panova-Noeva M; Vignoli A; Russo L; Barbui T; Falanga A
Thromb Haemost; 2010 Jul; 104(1):151-6. PubMed ID: 20431848
[TBL] [Abstract][Full Text] [Related]
8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
9. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Villamor N; Colomer D; Cervantes F
Haematologica; 2006 Feb; 91(2):169-75. PubMed ID: 16461300
[TBL] [Abstract][Full Text] [Related]
10. Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.
Petrides PE; Siegel F
Blood Cells Mol Dis; 2006; 36(3):379-84. PubMed ID: 16563815
[TBL] [Abstract][Full Text] [Related]
11. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
12. Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Villamor N; Jou JM; Cervantes F
Platelets; 2012; 23(5):336-43. PubMed ID: 22059534
[TBL] [Abstract][Full Text] [Related]
13. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
Hauschner H; Bokstad Horev M; Misgav M; Nagar M; Seligsohn U; Rosenberg N; Koren-Michowitz M
Am J Hematol; 2020 Apr; 95(4):379-386. PubMed ID: 31868244
[TBL] [Abstract][Full Text] [Related]
14. Circulating endothelial cells and endothelial activation in essential thrombocythemia: results from CD146+ immunomagnetic enrichment--flow cytometry and soluble E-selectin detection.
Belotti A; Elli E; Speranza T; Lanzi E; Pioltelli P; Pogliani E
Am J Hematol; 2012 Mar; 87(3):319-20. PubMed ID: 22190201
[TBL] [Abstract][Full Text] [Related]
15. Assessment of rotation thromboelastometry parameters in patients with essential thrombocythemia at diagnosis and after hydroxyurea therapy.
Treliński J; Okońska M; Robak M; Chojnowski K
Blood Coagul Fibrinolysis; 2016 Mar; 27(2):205-9. PubMed ID: 26829283
[TBL] [Abstract][Full Text] [Related]
16. The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.
Lambert JR; Gale RE; Linch DC
Br J Haematol; 2009 Apr; 145(1):128-30. PubMed ID: 19222478
[TBL] [Abstract][Full Text] [Related]
17. [Correlation of thrombosis with increased platelet turnover in essential thrombocythemia].
Gao XP; Liu ZM; Li J; Han XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb; 14(1):165-7. PubMed ID: 16584616
[TBL] [Abstract][Full Text] [Related]
18. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
Panova-Noeva M; Marchetti M; Buoro S; Russo L; Leuzzi A; Finazzi G; Rambaldi A; Ottomano C; Ten Cate H; Falanga A
Blood; 2011 Sep; 118(9):2599-601. PubMed ID: 21750318
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.
Treliński J; Wierzbowska A; Krawczyńska A; Sakowicz A; Pietrucha T; Smolewski P; Robak T; Chojnowski K
Leuk Lymphoma; 2010 Sep; 51(9):1727-33. PubMed ID: 20615083
[TBL] [Abstract][Full Text] [Related]
20. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
